Anemia is characterized by reduced quality of red blood cells, diminished hemoglobin levels, and even altered morphology of red blood cells. There are many forms of anemia, each with its cause and specific treatment; however, Iron deficiency anemia (IDA) is the most common type of anemia, accounting for over 50% of the total Anemic cases worldwide. As per DelveInsight, there were a total of 30,829,734 Iron Deficiency Anemia prevalent cases in 2020 in the 7MM (the US, EU5, and Japan), which is further anticipated to increase by 2030.
The Iron Deficiency Anemia Market is expected to witness growth at a CAGR of 3.7% in the 7MM during the forecast period (2021-30).
The therapies for Iron Deficiency Anemia are readily available and are inexpensive. However, the therapies are not only associated with physical problems but also with mental health side effects, which creates a need for effective, curative, and standard treatment options.
To bridge the gap between available therapies and demand for better patient outcomes, key pharma, and biotech companies such as Akebia Therapeutics (Keryx Pharmaceuticals), Torii Pharmaceutical, Shield Therapeutics, Norgine, and others are working to enhance the treatment scenario with novel therapies.
Read More: Key Companies in the Iron Deficiency Anemia Market